Regeneron Pharmaceuticals (NASDAQ:REGN) has been evaluated by 14 analysts over the last three months, with diverse opinions ranging from bullish to bearish. The average 12-month price target for REGN is $963.57, with a high of $1076.00 and a low of $800.00, marking a 6.73% increase from the previous target of $902.83. Analysts have made various rating actions, including maintaining, raising, and lowering their stances and price targets. Regeneron is involved in developing treatments for diseases and has several marketed products. The company's financial performance shows a revenue growth of 14.53%, a high net margin of 29.97%, an ROE of 4.12%, an ROA of 3.21%, and a low debt-to-equity ratio of 0.11.